| Literature DB >> 13680171 |
Dieter Buchheidt1, Angelika Böhme, Oliver A Cornely, Gerd Fätkenheuer, Heinz-Georg Fuhr, Gudula Heussel, Christian Junghanss, Meinolf Karthaus, Olaf Kellner, Winfried V Kern, Xaver Schiel, Orhan Sezer, Thomas Südhoff, Hubert Szelényi.
Abstract
Approximately 85% of patients with acute leukemia undergoing intensive antileukemic treatment develop infections and/or fever during neutropenic phases; in about 50% of these patients clinical, microbiological or clinical and microbiological evidence of infections can be obtained. The response rate is significantly lower in documented infections than in fever of unknown origin (FUO). Evidence-based recommendations for diagnosis and treatment procedures are presented, reflecting study results and expert opinions.Entities:
Mesh：
Year: 2003 PMID： 13680171 DOI： 10.1007/s00277-003-0766-2
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673